Press-release for stocks for TPTX

symbols : TPTX

save search

BlossomHill Therapeutics Closes $100 Million Series B Financing
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
TPTX | $76.01 -0.03%

Health Technology

| Email alert Add to watchlist
million series therapeutics

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -2.41% | O: 0.15% H: 0.59% C: 0.37%
therapeutics

Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | News | $3.882 -0.46% 0.0% 340

Finance

| -1.02% | O: -3.19% H: 4.87% C: 4.87%
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -13.46% | O: -4.68% H: 2.46% C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 6.54% | O: 0.16% H: 0.47% C: 0.2%
financial results

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K

Health Technology

| -36.47% | O: 2.31% H: 10.14% C: 8.87%
granted tumors treatment designation china therapy

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K

Health Technology

| -43.33% | O: -1.12% H: 1.1% C: 0.38%

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
Published: 2023-05-18 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K

Health Technology

| -54.87% | O: 1.19% H: 0.0% C: -7.17%
review

Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | News | $289.67 3.83% 5.3K

Health Technology

| -30.92% | O: 0.24% H: 0.66% C: 0.66%
NVSEF | News | $95.11 6.88% 490

Health Technology

| 10.61% | O: -1.1% H: 0.0% C: 0.0%
TAK | News | $13.38 0.15% 0.9% 1.7M

Health Technology

| -18.32% | O: 0.61% H: 0.3% C: 0.24%
NVS | News | $97.28 2.27% 0.31% 3.7M

Health Technology

| -5.68% | O: 0.2% H: 0.13% C: -0.22%
GSK | News | $41.24 1.6% 0.0% 2.3M

Health Technology

| 12.89% | O: 0.27% H: 0.6% C: 0.41%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -11.83% | O: 0.38% H: 0.0% C: 0.0%
GMAB | News | $28.54 -1.48% -1.51% 560K

Health Technology

| -31.49% | O: 0.38% H: 0.91% C: 0.69%
AMGN | News | $273.69 0.66% 0.65% 2.5M

Health Technology

| 17.42% | O: 0.14% H: 0.28% C: 0.11%
report cancer global therapy growth market

Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
Published: 2022-10-26 (Crawled : 05:00) - biospace.com/
TSVT | $4.63 -0.43% -0.43% 290K

| -68.71% | O: 0.37% H: 5.32% C: 4.04%
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -32.68% | O: 0.44% H: 2.9% C: 1.86%
financial

Gastrointestinal Stromal Tumor Market is Expected to Grow at a CAGR of 13.8% by 2032 | DelveInsight
Published: 2022-09-26 (Crawled : 16:00) - prnewswire.com
EXEL | $23.295 1.86% 1.82% 1.9M

Health Technology

| 43.06% | O: 0.06% H: 0.98% C: -2.46%
COGT | $6.99 -1.83% -1.86% 1.2M

Health Technology

| -50.36% | O: -0.71% H: 4.22% C: 3.38%
BPMC | $92.32 1.89% 1.85% 790K

Health Technology

| 40.75% | O: -0.53% H: 2.33% C: -3.22%
expected gastrointestinal market

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Published: 2022-08-17 (Crawled : 13:20) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -33.91% | O: -0.3% H: 1.45% C: 0.88%
acquisition

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
Published: 2022-08-16 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -34.27% | O: -0.23% H: 1.0% C: -0.31%
TPTX | $76.01 -0.03%

Health Technology

| 0.75% | O: 0.75% H: 0.0% C: 0.0%
acquisition clearance therapeutics germany

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
TPTX | $76.01 -0.03%

Health Technology

| 0.98% | O: -0.27% H: 0.0% C: 0.0%
therapeutics

Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
Published: 2022-07-27 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -33.46% | O: -1.68% H: 3.58% C: 3.34%
TPTX | $76.01 -0.03%

Health Technology

| 1.36% | O: -0.01% H: 0.28% C: 0.11%
IMTX | $10.4 2.06% 2.02% 380K

Health Technology

| -7.3% | O: 0.53% H: 2.04% C: 0.27%

Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
Published: 2022-07-19 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology